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Abstract
Bone marrow was recently proposed as an alternative and potentially immune-privileged site for pancreatic islet
transplantation. The aim of the present study was to assess the survival and rejection mechanisms of free and encapsulated
xenogeneic islets transplanted into the medullary cavity of the femur, or under the kidney capsule of streptozotocin-
induced diabetic C57BL/6 mice. The median survival of free rat islets transplanted into the bone marrow or under the kidney
capsule was 9 and 14 days, respectively, whereas that of free human islets was shorter, 7 days (bone marrow) and 10 days
(kidney capsule). Infiltrating CD8+ T cells and redistributed CD4+ T cells, and macrophages were detected around the
transplanted islets in bone sections. Recipient mouse splenocytes proliferated in response to donor rat stimulator cells. One
month after transplantation under both kidney capsule or into bone marrow, encapsulated rat islets had induced a similar
degree of fibrotic reaction and still contained insulin positive cells. In conclusion, we successfully established a small animal
model for xenogeneic islet transplantation into the bone marrow. The rejection of xenogeneic islets was associated with
local and systemic T cell responses and macrophage recruitment. Although there was no evidence for immune-privilege, the
bone marrow may represent a feasible site for encapsulated xenogeneic islet transplantation.
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Introduction
The incidence of type 1 diabetes is constantly rising in children
and adolescents since the mid-1950’s [1,2]. Allotransplantation of
pancreatic islets is currently an option for the treatment of diabetic
type-I patients suffering from repetitive and severe hypoglycemic
episodes. However, the possibility of receiving an islet transplant is
limited mainly due the shortage of organ and the need for life-long
immunosuppression. The utilization of islets from other species
(xenograft) and administration in encapsulated form represent
attractive strategies to overcome both problems.
Clinical trials of allogeneic human or xenogeneic pig encapsu-
lated islets have been reported in only a few cases [3,4]. After
intra-peritoneal transplantation all patients showed a modest
reduction in insulin requirement and a significant diminution of
hypoglycemic episodes without any detectable immune response
against the islets. Nevertheless, sustained insulin-independence was
not achieved after encapsulated allogeneic islet transplantation. In
addition, blood porcine C peptide levels remained low or
undetectable suggesting graft failure. Certain investigators are of
the opinion that this poor outcome is related to the high sensitivity
of pancreatic islets to hypoxia [5]. Indeed, islets are highly
vascularized structures depending on an arterial oxygen supply of
40 mmHg [6]. The peritoneum, although it allows the implanta-
tion of a large volume of islets, suffers from low oxygen pressure
and limited vascularization [7,8].
Recently the bone marrow (BM) has been proposed as an
alternative site for autologous and allogeneic islet transplantation
because it is considered to be well-vascularized and easily
accessible [9,10]. Syngeneic islets reverse diabetes without
compromising the hematopoietic activity [11]. Recently, The
group of Piemonti has reported the first unequivocal example of
successful engraftment of autologous islets in human BM for up to
944 days [9]. While direct differentiation of hematopoietic stem
cells into islet cells is highly unlikely, a wide array of experimental
evidences indicates that cells of BM origin are capable of
facilitating the survival, reorganization and revascularization of
the islets [12–15]. Finally, it has been suggested that BM is an
immune privileged site. Histological findings in the rat tibia
showed intact islet allografts three weeks after transplantation
without any immunosuppression [16]. Thus, the BM could
represent a potential alternative transplantation site for encapsu-
lated islet xenograft.
The aim of this study was to establish an animal model for
xenogeneic islet transplantation into BM. We assessed the survival
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of xenogeneic rat and human pancreatic islets transplanted into
the BM of mice and characterized the ensuing immune responses.
In addition we investigated the feasibility of transplanting
encapsulated Sprague Dawley rat islets to the femur of C57BL/
6 mice. It should be noted that in vivo functional assays with
encapsulated islets under the kidney capsule (KC) or into the BM
were not feasible due to space limitations.
Materials and Methods
Animals
Pancreatic islets were harvested from adult Sprague-Dawley rats
with a weight of 250–300 grams and transplanted into C57BL/6
mice between 6–10 weeks of age (Centre de Recherche et
d’Elevage, Janvier, France). Animals were maintained in conven-
tional housing facilities and all experiments were performed in
compliance with the bylaws of Geneva veterinary authorities and
were approved by the ethical committee of the Geneva University
Medical School (Protocol Nr. 1014/3767/2).
Human Pancreatic Islets
Human islets were isolated according to the Ricordi protocol
with local adaptation [17]. Human islets used in this study had a
minimum purity of 80% as assessed with Metamoph software
(MetaMorph, Universal Imaging, West Chester, PA) as previously
described [18]. The use of human islet preparations for
experimental research was approved by the Institutional Review
Board for clinical research of the Departments of Neurology,
Dermatology, Anesthesiology and Surgery of the University
Hospital of Geneva (CER Nr. 05–028). Our ethical institution
waived the need for consent from the donor. Islets were used for
experimental research only when not suitable for clinical purposes
and with the intention to be destroyed. In such cases, obtaining
informed consent is not mandatory in Switzerland. Tissues
samples were not procured from a tissue bank.
Rat Pancreatic Islets
Rat pancreases were perfused with collagenase type XI, 1 mg/
ml (Sigma, Buchs, Switzerland), removed surgically, and enzy-
matically digested in vitro at 37uC for 10 minutes as previously
described [19]. Islets were then purified by Ficoll density gradient
centrifugation and maintained on ice prior to transplantation.
Figure 1. Transplantation of syngeneic islets into the bone marrow. A 22-gauge needle was used for injection of the syngeneic islets into the
bone marrow of C57BL/6 through the distal part of the femur (A). Transplanted mice remained normoglycemic over 30 days (B). Intraperitoneal
glucose tolerance test was performed after 30 days in transplanted and naı¨ve mice. Error bars represent the standard deviation. (C). Bones were
harvested after 30 days and stained for haematoxylin and eosin (D), insulin (E) and glucagon/insulin (F). Glucagon positive cells appear in red whereas
insulin positive cells appear in green. Scale bar 500 mm (D,E), 100 mm (F).
doi:10.1371/journal.pone.0091268.g001
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Islet Transplantation
Diabetes was induced in the recipient mice by a single
intraperitoneal (i.p.) injection of streptozotocin (Sigma, Buchs,
Switzerland), 220 mg/kg. Only diabetic mice with blood sugar
levels of .20 mmol/L were used for the transplantation of 1000
rat and 3000 human islets equivalent (IEQ), either into the BM or
under the kidney capsule (KC) of diabetic mice. Higher numbers
of human islets are required to reverse hyperglycemia due to
murine resistance to human insulin [20–21]. Islets were compact-
ed in a pellet and rapidly transplanted into the BM or under the
KC as prolonged compaction of the islets can affect their survival
[22].
In accordance with the 3R principles of animal experimentation
(reduce, refine, replace), only half of the rat islets were transplanted
in experiments using non-diabetic mice. Islets were inserted in a
22-gauge butterfly as previously described [19]. For transplanta-
tion into the BM a medial incision was made to the anterior
surface of the knee of the mice. A 29-gauge needle followed by a
22 gauge was inserted into the distal part of the femur to prepare
the pathway for the islets. The islets were slowly injected using a
22-gauge needle (Figure 1A). After careful retraction of the
injection needle the skin was closed with 5.0 sutures. Islet graft
function was assessed by regular blood sugar determination
(Precision Q.I.D). Blood sugar levels of ,13 mmol/l were
considered as successful islet transplantation, whereas levels of .
20 mmol defined graft failure.
Islet Encapsulation
Encapsulation in Ca-alginate was performed as previously
described [23]. Briefly, a stock solution of ultrapure sodium
alginate (Na-alg, Pronova UP LVM; batch No FP-506-01, FMC
BioPolymer, Norway) was prepared with a final concentration of
1.5% w/v in Dulbecco’s Modified Eagle Medium (DMEM, Cell
Culture Technologies LLC, Gravessano, Switzerland). The islets
were suspended in the 1.5% Na-alg stock solution (109000 IEQ/
ml), homogenized, and finally extruded into the gelation bath
(CaCl2, 110 mM) using a coaxial airflow droplet generator (Buchi,
Basel, Switzerland). Beads were gelled at 37uC for 15 min,
collected by filtration, washed twice with DMEM, and cultured at
37uC. Encapsulated islets were transplanted using an 18 gauge
needle. The average bead size was in the range of 450–500 mm.
Histological Analyses
Paraffin. For morphologic evaluation kidney samples were
preserved in formalin 10%, fixed in 4% paraformaldehyde,
decalcified, embedded in paraffin and sectioned. Paraffin sections
(5 um) were used for haematoxylin and eosin (H&E) staining.
Paraffin sections were incubated using guinea pig anti-insulin
antibody (1:100 dilution, Invitrogen, Basel, Switzerland) and
rabbit anti-glucagon (dilution 1:200, Dako, Denmark), and
subsequently with goat anti-guinea pig IgG Alexa 488-conjugated
(1:1000 dilution, Invitrogen) and anti-rabbit IgG Alexa 566
(Dilution 1:1000, Life Technologies, Carlsbad, CA). Alternatively,
paraffin sections were stained with guinea-pig anti- insulin
antibody, subsequently anti-guinea-pig IgG Alexa 488, and
thereafter with 0.09% Evans blue at the termination of the
procedure.
Cryostat. Kidney and BM samples were harvested three days
following islet transplantation, stored at –80uC and used for
immunofluorescence staining. Briefly, frozen sections were incu-
Figure 2. Free xenogeneic islet survival. Streptozotocin-induced diabetic mice were transplanted with rat (A-B-C) or human (D-E-F) pancreatic
islets either in the bone marrow (BM) or under the kidney capsule (KC). The glycemic profile was followed over time in all groups. The median survival
of rat islets was 9 days when transplanted into the BM (n = 7) and 14 days when transplanted under the KC (n = 8) (A-B-C). The median survival of
discordant human islets was shorter in both sites with 7 and 10 days respectively in the BM (n = 11) and under the KC (n = 11) (D-E-F).
doi:10.1371/journal.pone.0091268.g002
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bated for two hours with rat anti-mouse CD4 (550278, 1:50
dilution, Becton Dickinson), rat anti-mouse CD8 (MCA 609G,
1:100 dilution, Serotec), or F4/80 antibodies (MCA 497, 1:50
dilution, Serotec) to detect macrophages. Secondary staining was
performed with anti-rat IgG Alexa 555-conjugated (1:1000
dilution, Invitrogen). Thereafter, the slides were stained for insulin
as described for the paraffin section (1:1000 dilution, Invitrogen).
The sections were then mounted and viewed under a fluorescent
microscope (Zeiss).
Flow Cytometry
Seven days post-transplantation, femurs bearing islet grafts,
contralateral femurs, and spleens were processed for flow
cytometry analysis. Naive mice were used as negative controls.
Figure 3. Characterization of the rejection in the bone marrow after rat islets transplantation. (A–C) Seven days post-transplantation,
animals were sacrificed for the characterization of rejection. The graft-bearing femur (n = 5), the opposite control femur (n = 4) and the femur of non-
transplanted animals (n = 4) were harvested, flushed and the cells analyzed by flow cytometry. The percentage of CD8+ (A) cells in transplanted
femurs was significantly increased whereas percentages of CD4+ (B) and F4/80+ (C) cells remained unchanged compared to the non-transplanted
contralateral control femurs. Box-and-whisker diagram are shown. (D–F) Alternatively, the femurs of graft bearing-femurs (D–F) and the contralateral
femurs (G–I) were frozen in liquid nitrogen and double stained for insulin (green) and CD8 (D/G), CD4 (E/H) or F4/80 (F/I) (red) three days post
transplantation. Scale bar 50 mm. (J) CD4+, CD8+ and F4/80+ cells were quantified using the MetaMorph software. The levels of CD4+ and F4/80+ cells
were similar between both groups; CD8+ cells were significantly more abundant in femurs containing the islet graft. Abbreviation. Tx Cont:
contralateral femur. TX D7: graft bearing femur.
doi:10.1371/journal.pone.0091268.g003
Islet Xenotransplantation in the Bone Marrow
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e91268
Bones were flushed with PBS and spleens were smashed with the
back of the piston of a 1 ml syringe. Red blood cells were lysed
before counting (Pharm Lyse BD Bioscience San Jose CA). Due to
the techniques used for cutting and flushing the bones, the
absolute number of cells harvested was variable between samples
(Figure S1). Samples of 200’000 BM cells or splenocytes were
stained with anti-CD4 (APC Cy7, RM4–5 eBioscience San Diego,
CA), anti-CD8 (PerCP 53-6.7, eBioscience), and F4/80 antibodies
(APC, CI:A3-1, Serotec). Irrelevant isotype control antibodies
included rat IgG2b APC-Cy7, rat IgG2a PerCP, and rat IgG2b
APC. Data were collected on a FACScanto (Becton Dickinson,
Franlin Lakes, NJ). All data were analyzed using Flowjo software
(Tree Star v. 8.7.3, Ashland, OR).
Mixed Lymphocyte Reaction
One-way mixed lymphocyte reactions were performed seven
days post-transplantation between donor Sprague Dawley rat T-
cell-depleted splenocytes and recipient C57BL/6 splenocytes.
Briefly, rat donor splenocytes were harvested on the same day as
the islets. After red blood cell lysis, the cells were stained with
mouse anti-rat CD3-PE antibody (OX-38, BD bioscience)
followed by negative selection using LD columns (Miltenyi Biotec,
Bergisch Gladbach, Germany). This procedure resulted in an over
95% pure CD3–depleted cell population which was frozen until
seven days post islet transplantation. A total of 2.56105
splenocytes obtained from transplanted or naive control mice
were co-cultured with 46105 irradiated (3500 rad) T cell-depleted
rat donor splenocytes for 5 days. Cells were then pulsed with
1 mCi3[H] of thymidine for 18 hours and harvested.
MetaMorph Quantification
The total surface of positive collagen staining on bone and
kidney sections was determined using the morphometric quanti-
fication software (Universal Imaging). Thus, the blue area
(collagen I to VI) was normalized to the red area (cells) on
Masson’s trichrome staining and the number of capsules. Bone
surfaces, which constitutively stain blue, were excluded. Alterna-
tively, the number of CD4, CD8 and F4/80-positive cells was
counted at 2006magnification on images of bone sections (8–11
fields per group out of three animals) using offline MetaMorph
imaging software for microscopy. The number of positive cells was
normalized with the total number of cells per 2006magnification
fields (Hoechst positive cells counted using MetaMorph software)
and expressed as a percentage.
Insulin Secretion test
This test was performed using encapsulated rat islets after 30
days of culture. Insulin release in response to acute glucose
stimulation was determined by incubating the islets for 1 hour in
RPMI 10% FCS medium containing low glucose (2.8 mM) for
basal secretion, followed by an additional hour of incubation in
high glucose (16.8 mM) medium or 16.8 mM glucose medium
supplemented with 5 mM of theophylline. Supernatants were
collected, frozen and insulin concentrations were determined using
rat insulin ELISA Kit according to the manufacturer’s instructions
(Mercodia, Uppsala, Sweden). Results were normalized to the total
insulin content of the islets as measured by the same ELISA kit
and following ice-cold acid-ethanol extraction. Due to inter-
experimental variability, and depending upon the time of culture
and the encapsulation, insulin secretion was expressed relative to
the basal levels (stimulation index).
Intraperitoneal Glucose Tolerance Test (IPGTT)
Animals were maintained on a standard diet overnight, and
then injected intraperitoneally with a 2 g/kg glucose solution re-
suspended in PBS. Blood samples were collected after 0, 5, 15, 30,
60, 90, 120 and 180 minutes.
Figure 4. Characterization of the splenocytes after rat islet transplantation into the bone marrow. The splenocytes of transplanted and
naive animals were harvested seven days after transplantation. The absolute number of splenocytes was not significantly different compared to naive
mice; data are shown for individual animals with the horizontal line representing the mean value (A). The percentages of CD4+, CD8+ and F4/80+ cells
were not significantly different either. Box-and-whisker diagram are shown (B). However, splenocytes of transplanted mice showed a significantly
increased level of proliferation compared to naive mice when stimulated by donor (T cell-depleted) rat irradiated splenocytes. Results are expressed
in counts per minute and show the mean value of 4 naive and 6 transplanted animals (C). Abbreviation. Tx: transplanted. CPM: Count per minutes.
doi:10.1371/journal.pone.0091268.g004
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Statistical Analysis
Prism software was used for statistical analysis (GraphPad
Software, San Diego California, USA). Survival curves were
calculated by the Kaplan and Meier method and analyzed using
the Cox-Mantel test. Flow cytometry results were analyzed using
the Krukal-Wallis and Dunn’s multiple comparison tests. The
Mann-Whitney U test was used for mixed lymphocyte reaction
and MetaMorph quantification. A p-value inferior to 0.05 was
considered statistically significant.
Results
Injection of Islets into the Bone Marrow
Syngeneic islets were injected into the femur of diabetic mice
through the knee (Figure 1A). The transplanted mice remained
normoglycemic indefinitely (Figure 1B). Sham transplantation into
the bone marrow did not alter the weight gain of the mice as
compared to naive mice (Figure S2). Intraperitoneal glucose
tolerance testing was performed on day-30 post-transplantation
and showed a similar glucose tolerance profile between trans-
planted and naive control mice (Figure 1C). Thirty days after
transplantation bone was harvested and stained for H&E (1D),
insulin (1E) and insulin/glucagon (1F). Of note, islets must be
slowly injected into the BM since rapid injection may provoke
pulmonary embolism and consequently the death of the animal
(Figure S3). Removal of the graft-bearing femur resulted in animal
death rapidly after the procedure, before reversion to hypergly-
cemia (n = 4, data not shown).
Survival of Concordant Rat and Discordant Human islets
Xenograft
We next investigated the survival of concordant rat and
discordant human islets transplanted into the BM and KC of
streptozotocin-induced C57BL/6 diabetic mice. One thousand rat
islets equivalent (IEQ) and 3000 human IEQ were used for
prompt reversal of diabetes after transplantation into the BM
(Figure 2A–F). The median survival of free rat islets was 9 days
when transplanted into the BM (n = 7) and 14 days when
transplanted under the KC (n = 8) (2A–C). The median survival
of discordant human islets was shorter at both sites, 7 and 10 days
respectively in the BM (n = 11) and under the KC (n = 11) (2D–F).
Thus, there was no evidence for an immune-privileged environ-
ment in the BM for neither concordant nor discordant islet
xenograft.
Figure 5. Survival and function of encapsulated rat islets in vitro. Viability was assessed over 30 days in vitro by fluorescein diacetate (green)
and propidium iodide (red). Encapsulated islets remained viable over 30 days of culture. Scale bar 200 mm (A). The function of the encapsulated islets
was tested in vitro 30 days post encapsulation by glucose stimulated insulin secretion test. Islets were incubated in medium with 2.8 mM glucose,
16.8 mM glucose and 16.8 mM glucose supplemented with theophylline. The stimulation index was respectively 2 (glucose-stimulated) and 5
(theophylline-stimulated). The mean and SEM are shown of one representative experiment out of three (B).
doi:10.1371/journal.pone.0091268.g005
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Characterization of Islet Graft Rejection in the Bone
Marrow
Due to the immunosuppressive effects of the streptozotocin [24]
we further characterized the rejection of free rat islets in non-
diabetic mice. By flow cytometry we first assessed the percentages
of CD4+, CD8+, and F4/80+ cells in the BM. The graft-bearing
femurs and the contralateral femur of transplanted mice were
harvested seven days post-transplantation and flushed. Femurs of
non-transplanted naive mice were also used as controls. Absolute
numbers of cells in the femurs of the three groups were similar
(Figure S1). Within the total cell population we found a significant
increase of the percentage of CD8+ cells in transplanted femurs,
whereas percentages of CD4+ and F4/80+ cells remained
unchanged (Figure 3A–C). Three days post-transplantation the
graft bearing-femurs (3D–3F) and the contralateral femur (3G–I)
were frozen in liquid nitrogen and double stained for insulin and
CD8 (3D/G), CD4 (3E/H) or F4/80+ (3F/I). Densities of CD4+,
CD8+ and F4/80+ cells were markedly increased around islets
(Figure 3D–F). Quantitative data of the immunochemistry staining
revealed that the amount of CD4+ and F4/80+ cells were similar
between both groups and that CD8+ cells were more abundant in
femurs containing the islet graft compared to controls (Figure 3J).
Altogether, these results suggest that islet transplantation induced
the proliferation of CD8+ cells in the BM, and rejection was
mediated at least partly through the recruitment of CD4+, CD8+
and macrophages.
Antigen Recognition in the Spleen after Xenogeneic Islet
Transplantation
Because BM itself is a lymphoid tissue the immune response
induced by the presence of xenogeneic islets could remain
localized in the femur. To assess a potential systemic immune
response we harvested the spleen of non-diabetic mice for
phenotypic and functional assays seven days after rat islet
transplantation. The absolute number of harvested cells was not
significantly different compared to naive mice (Figure 4A). The
percentages of CD4+, CD8+ and F4/80+ cells were also not
significantly different (Figure 4B). However, splenocytes of
transplanted mice compared to naive mice showed a significantly
increased proliferation when stimulated by donor (T cells-
Figure 6. Encapsulated rat islets one month after transplantation. Encapsulated rat islets were transplanted under the kidney capsule (KC)
(A–C) or into the bone marrow (BM) (D–F) One month after transplantation the femur and kidney were harvested. Haematoxylin and eosin staining
showed intact capsules in the KC (A) and BM (D). Insulin staining confirmed the survival of the rat islets (B, E). The pericapsular fibrotic reaction was
assessed by Masson’s coloration (C, F). The collagen/capsule surface ratio was quantified using MetaMorph software (G). Data presented are mean
values 6SEM out of three (bone marrow) and four (kidney capsule) animals. Scale bar 100 mm (A,B,D,E), 1000 mm (C,F).
doi:10.1371/journal.pone.0091268.g006
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depleted) rat splenocytes (Figure 4C), suggesting that antigenic
recognition of the xenogeneic islets occurred in the spleen.
Encapsulated Rat Islets Survived More than One Month
in vitro and in Bone Marrow
As a next step we assessed the feasibility of transplanting
encapsulated rat islets into the BM. The viability of the islets was
confirmed in vitro by fluorescein diacetate and propidium iodide up
to 30 days after encapsulation (Figure 5A). At day 30 encapsulated
islets still responded to glucose and theophylline stimuli (Figure 5B).
We next transplanted encapsulated rat islets into the BM and
under the KC of non-diabetic mice. After 30 days the femur and
kidney were harvested, and H&E staining showed intact capsules
at both sites (Figure 6A, 6D). Additionally, the islets in the capsules
stained positive for insulin and DAPI suggesting that they survived
in vivo (Figure 6B, 6E). In vivo functional assays could not be
performed in the femur or under the KC because transplantation
of sufficient numbers of encapsulated islets was not possible due to
space limitations (data not shown). Finally, we quantified the
fibrotic reaction against the capsules (Figure 6C, 6F) Similar levels
of fibrosis were present under the KC and in the BM, after
exclusion of the bone structures which constitutively contain
collagen (Figure 6G). Of note, fibrosis does not develop after
transplantation of syngeneic islets under the kidney capsule or into
the BM (data not shown).
Discussion
The overall goal of this study was to establish a small animal
model to evaluate the BM as a potential transplantation site for
free and encapsulated islet xenografts. The rational of transplant-
ing islets into the BM is based on the accessibility of the site with
the possibility for repeated infusions, and on the extravascular but
well vascularized bone microenvironment [11]. The liver, the
currently used site for islet transplantation, has several disadvan-
tages including: (i) immediate blood-mediated inflammatory
reaction (IBMIR) characterized by the activation of complement,
platelets and coagulation as well as neutrophil recruitment,
induces the loss of as many as 50–75% of islets during engraftment
[25]; (ii) risk for hemorrhages associated with the infusion through
the liver parenchyma into the portal vein; and (iii) increase of
portal pressure during the procedure which limits both the
number and mass of administered islets, and precludes the
transplantation of encapsulated islets with a diameter up to
500 mm [26]. The emerging perspective of transplanting encap-
sulated xenogeneic, i.e. porcine islets, into humans prompted us
therefore to analyze the BM as an alternative transplantation site.
Transplantation into the BM of 1000 rat IEQ and 3000 human
IEQ per mice was required in order to reverse diabetes, which is
2–3 times higher than what is required for a xenogeneic islets
transplant under the KC [19]. There are several reasons for this
finding. First, the injection procedure through the spongy
framework of the femur may be associated with loss due to
substantial mechanical stress. Secondly, direct blood contact with
the islets in the BM may provoke an IBMIR as occurs in the liver.
Furthermore, IBMIR is even enhanced due to the xenogeneic
tissue [27]. Finally, the release of insulin may be less efficient in the
BM than under the KC. Nevertheless, as shown in a syngeneic
mouse model, islets transplanted into the BM progressively
normalized glycaemia with maximal function 3 to 4 weeks after
transplantation, with a 2.4-fold higher probability to reach
euglycaemia when compared to intraportal islet transplantation
[11]. Of note, we cannot exclude that ischemia time and donor
characteristics affected the function and viability of the human
islets used in this study, and thus may have influenced the survival
rates after transplantation. Altogether, our results confirmed that
xenogeneic islets transplanted into the BM could normalize blood
glycaemia in a xenogeneic model. However, further studies are still
warranted in larger animal models to better define the advantages
and limitations of the BM as a potential site for xenogeneic islets.
Our second aim was to analyze the rejection process of non-
encapsulated xenogeneic islets transplanted into the BM. The
median survival of free rat and human islets was shorter in the BM
than under the KC, excluding any immune privileged environ-
ment in the BM [11]. In contrast to vascularized organs that are
highly sensitive to antibody-mediated rejection through comple-
ment activation, xenogeneic islets are mainly rejected by cellular-
dependent mechanisms [28]. In particular CD4+ T cells play a
critical role in the initiation of a Th2-like immune response by the
recruitment of macrophages [29–31]. CD8+ T cells are also
capable of rejecting pancreas islet xenograft in the absence of
CD4+ T cells [32] although it is not considered to be the primum
movens for rejection of cellular grafts in xenotransplantation. Our
study confirmed the presence of macrophages and CD4+ and
CD8+ T cells infiltrating the islet xenograft, which suggests that the
mechanisms responsible for rejection in the BM are similar to
those that have been previously described. In vivo depletion studies
would be required to differentiate the respective role of each cell
subset knowing that the mechanisms of cell-mediated islet
xenograft rejection are characterized by redundancy [28]. In
addition, further analysis of the cellular surface markers and
cytokines secretion profile would give more information of the role
of each cell subsets during islet rejection into the BM.
Seven days after islet transplantation the spleens were harvested.
There were no changes found in the frequencies of CD4+, CD8+
and macrophages, although splenocytes proliferated in response to
donor antigen when compared to naive animals. This suggests that
the islet xenograft elicited an immune response through CD4
priming in the spleen. Antigen recognition triggers xenograft
immunity via direct pathways involving interspecies TCR/MHC
interaction and indirect pathways through the presentation of
xenogeneic peptides by recipient dendritic cells [33,34]. In the
absence of recipient antigen presenting cells (APC), the strength of
the cell-mediated xenograft rejection becomes weaker suggesting
that indirect antigen presentation is crucial for xenogeneic islet
immunity [28]. Thus, our study confirmed that the immune
response against xenogeneic islets was induced not only in the BM
itself but also in secondary lymphoid organs such as the spleen.
This could be mediated by passenger leukocytes migrating into the
spleen or via free xenoantigens entering the peripheral circulation
[35].
The last aim of this study was to assess the feasibility of
transplanting encapsulated xenogeneic islets into the BM.
Although the available space in the BM of mice was not sufficient
to perform functional assays, insulin-positive islets could be
retrieved one month after transplantation. The encapsulated islets
were intact and did not induce a higher level of fibrosis as
compared to the KC, despite the presence of an abundant cellular
environment in the BM. Peri-capsular fibrotic overgrowth has
been recognized as an important factor leading to failure of the
encapsulated islets transplanted into the peritoneum [5,36].
Fibrosis is induced by physical irregularities of the capsule [37],
or by macrophages recruited via the chemokines secreted by the
islets [36,38]. To diminish the fibrotic reaction against the
xenogeneic islets, the alginate beads could be chemically
manipulated with polyethylene glycol reducing the pro-inflamma-
tory properties associated with polycation-coated alginate micro-
spheres [39,40]. Altogether, the transplantation of encapsulated
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islets into the BM was feasible without inducing an extensive peri-
capsular fibrosis. Nevertheless, further studies are necessary in a
larger animal model with larger bones, such as the pig, in order to
perform functional assays.
Except for the survival experiments that included rat and
human islets, the analysis in the present study was based on the
rejection of rat islets. Because only a few studies have compared
the rejection of concordant (rat) and discordant (human) islets in
the mouse model, it remains difficult to predict whether the
present results for rat islets will be similar for human islets. First,
the innate response composed by neutrophils, macrophages and
natural killer cells plays an active role in discordant transplantation
[41]. Second, the rejection depends on the ability of donor antigen
presenting cells (APC) to efficiently present antigen to the helper
and effector T cells. In discordant islet transplantation indirect
presentation of antigens (by recipient APC) is a major pathway for
islet rejection, whereas in concordant and allogeneic islets
transplantation both recipient and donor APC participate in the
rejection process [42–43]. In particular, the depletion of recipient
macrophages (which include APC) prolongs the survival of human
but not rat islets, suggesting a critical role for indirect antigen
presentation in discordant transplantation [43]. Further studies are
still warranted to compare rejection of concordant and discordant
islets transplanted in the BM.
In conclusion, the present study demonstrated that the BM
represents a potential alternative site for xenogeneic encapsulated
islets. Caution has to be taken during islet injection due to the risk
of pulmonary embolism. The mechanisms of xenograft rejection in
the BM seemed to depend at least partially on macrophages and
CD4+ and CD8+ T cells, with the caution that other cell types such
as neutrophils or natural killer cells have not been analyzed and
the antibody mediated rejection has not been evaluated. The
physiological disproportion between the size of the murine femurs
and the required volume of injected encapsulated islets did not
allow us to study graft function in greater detail. Nonetheless, if
these encouraging results can be reproduced in a large animal
model they may open new perspectives for the transplantation of
encapsulated xenogeneic islets into the BM in humans.
Supporting Information
Figure S1 Absolut numbers of cells harvested from the
bone marrow. The graft-bearing femurs and the contralateral
femur of transplanted mice were harvested seven days post-
transplantation and flushed. Femurs of non-transplanted naive
mice were also used as controls. Due to technical issues, the
absolute numbers of cells in the femurs were variable between
samples. No significant differences were found between the groups.
(TIFF)
Figure S2 Weight gain of mice after sham islet trans-
plantation into bone marrow compared to naı¨ve mice.
The weight of C57BL/6 mice following sham islet transplantation
(white triangles) was monitored and compared to those of naı¨ve
mice (white squares). The transplantation procedure did not alter
the weight of the mice.
(TIFF)
Figure S3 Injection of islets into the bone marrow can
provoke fatal pulmonary embolism. Rapid injection of free
islets into the bone marrow may be associated with fatal
pulmonary embolisms. Air bubbles can be visualized through
the inferior vena cava if injected rapidly into the femur (black
arrow) (A). The lungs of the animals were harvested and stained
with haematoxylin and eosin and showed solid aggregates in the
pulmonary vessels (B). Haematoxylin and eosin staining, scale bar
100 mm.
(TIFF)
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